0RN4.LSE Oncopeptides AB (publ)
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 0RN4.LSE undervalued?
Graham numberThe Graham number of Oncopeptides AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oncopeptides AB (publ) fundamental analysis
No fundamental analysis for Oncopeptides AB (publ) yet.
Oncopeptides AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic…
Full company profileFinancial statements of Oncopeptides AB (publ) are not available yet.
Oncopeptides AB (publ) dividends
Oncopeptides AB (publ) has not paid dividends in the last 4 fiscal years.
Who owns Oncopeptides AB (publ)
- Insiders 3.40%
- Institutions 12.98%
- Public & others 83.62%
- Free float 379M
Oncopeptides AB (publ) company profile
- Company name
- Oncopeptides AB (publ)
- Ticker
- 0RN4.LSE
- ISIN
- SE0009414576
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 69
- Fiscal year end
- December
- Address
- Luntmakargatan 46, Stockholm, Sweden, 111 37
- Phone
- 46 86 15 20 40
- Website
- oncopeptides.com/sv
About Oncopeptides AB (publ)
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB (publ) management
10- Ms. Sofia Heigis M.Sc.Chief Executive Officer · born 1980
- Prof. Rolf Larsson M.D., Ph.D.Founder
- Prof. Rolf Lewensohn M.D., Ph.D.Founder
- Dr. Joachim Gullbo M.D., MSc Pharm, Ph.D.Founder
- Dr. Kristina Luthman Ph.D.Founder
- Prof. Hans Ehrsson M.D.Founder
- Mr. Peter NygrenFounder · born 1959
- Mr. Henrik BergentoftChief Financial Officer · born 1974
- Ms. Eva Nordström M.Sc., MSc PharmCOO & Deputy MD · born 1970
- Mr. David AugustssonDirector of IR, Communications & Corporate Affairs · born 1984